Moreover, therapeutic blockade of the CD47/SIRPα axis using anti-CD47 mAbs has demonstrated efficacy in a variety of preclinical models and is currently in clinical trials for both leukemia and solid tumors (20). The gene discussed is CD47; the disease is leukemia.